New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease ...

The current human tissue-based study provides convincing evidence correlating hippocampal expressions of RNA guanine-rich G-quadruplexes with aging and with Alzheimer's Disease presence and severity.

Experts say there are ways to reduce our risk of dementia, including diet and exercise, protecting against hearing loss, and ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

This discovery is significant because there are currently no effective treatments for any type of dementia, including FTD.

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

They have identified a vital cellular mechanism driving the most common cause of dementia. American researchers say the breakthrough marks a "promising" target for drug treatments that slow ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.